This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Societal CDMO Crescita futura

Future criteri di controllo 1/6

Societal CDMO is forecast to grow revenue at 8.3% per annum.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.6%
Tasso di crescita dei ricavi	8.3%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	08 Apr 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Feb 10

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Feb 02

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Apr 29

Is Recro Pharma (NASDAQ:REPH) A Risky Investment?

Jan 06

Recro Pharma jumps 15% on Q1 result estimates beat

May 07

Would Shareholders Who Purchased Recro Pharma's (NASDAQ:REPH) Stock Year Be Happy With The Share price Today?

Feb 15

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:SCTL - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	111	N/A	13	N/A	1
12/31/2025	101	N/A	7	N/A	1
12/31/2024	95	-9	0	N/A	2
12/31/2023	95	-13	-9	-1	N/A
9/30/2023	91	-22	-11	-1	N/A
6/30/2023	89	-20	-10	1	N/A
3/31/2023	91	-20	-8	2	N/A
12/31/2022	90	-20	-12	-4	N/A
9/30/2022	88	-13	-9	-1	N/A
6/30/2022	85	-13	-4	2	N/A
3/31/2022	80	-9	-3	3	N/A
12/31/2021	75	-11	6	11	N/A
9/30/2021	63	-21	4	9	N/A
6/30/2021	64	-19	0	8	N/A
3/31/2021	62	-27	-3	6	N/A
12/31/2020	66	-28	0	8	N/A
9/30/2020	74	-21	-3	3	N/A
6/30/2020	80	-14	2	6	N/A
3/31/2020	96	-3	-17	-11	N/A
12/31/2019	99	5	-34	-25	N/A
9/30/2019	99	35	-42	-31	N/A
6/30/2019	92	17	-58	-47	N/A
3/31/2019	83	0	-49	-41	N/A
12/31/2018	77	-13	-50	-43	N/A
9/30/2018	79	-63	-40	-34	N/A
6/30/2018	77	-58	-37	-30	N/A
3/31/2018	73	-54	-31	-25	N/A
12/31/2017	72	-7	-22	-17	N/A
9/30/2017	70	-36	N/A	-17	N/A
6/30/2017	70	-33	N/A	-9	N/A
3/31/2017	70	-32	N/A	-8	N/A
12/31/2016	69	-30	N/A	-3	N/A
9/30/2016	69	-9	N/A	-4	N/A
6/30/2016	68	-6	N/A	1	N/A
3/31/2016	70	1	N/A	9	N/A
12/31/2015	52	3	N/A	8	N/A
9/30/2015	35	-11	N/A	4	N/A
6/30/2015	19	-14	N/A	-6	N/A
3/31/2015	N/A	-15	N/A	-13	N/A
12/31/2014	N/A	-17	N/A	-11	N/A
9/30/2014	N/A	-14	N/A	-7	N/A
6/30/2014	N/A	-10	N/A	-3	N/A
3/31/2014	N/A	-8	N/A	-2	N/A
12/31/2013	N/A	-2	N/A	-1	N/A
9/30/2013	N/A	-2	N/A	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if SCTL's forecast earnings growth is above the savings rate (2.3%).

Guadagni vs Mercato: Insufficient data to determine if SCTL's earnings are forecast to grow faster than the US market

Guadagni ad alta crescita: Insufficient data to determine if SCTL's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: SCTL's revenue (8.3% per year) is forecast to grow faster than the US market (8.1% per year).

Ricavi ad alta crescita: SCTL's revenue (8.3% per year) is forecast to grow slower than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if SCTL's Return on Equity is forecast to be high in 3 years time

This company has been acquired

Societal CDMO Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 14% to US$1.86

Societal CDMO, Inc. Resets Earnings Guidance for the Year 2023

Price target decreased by 18% to US$2.30

Consensus EPS estimates fall by 18%

Societal CDMO, Inc. Reaffirms 2023 Financial Guidance

Forecast to breakeven in 2025

Recent updates

Societal CDMO, Inc. Files Form 15

Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index

Societal CDMO's Common Stock to be Delisted from the Nasdaq Capital Market as a Result of the Merger with CoreRx

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc. (NasdaqCM:SCTL) from First Light Asset Management, LLC and Others for approximately $120 million.

New major risk - Share price stability

Now 29% overvalued after recent price rise

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Is Societal CDMO (NASDAQ:SCTL) Weighed On By Its Debt Load?

Price target decreased by 14% to US$1.86

High number of new directors

Nasdaq Grants Societal CDMO an Additional 180 Calendar Days to Regain Compliance with Minimum Bid Price Requirement

Societal CDMO, Inc. Resets Earnings Guidance for the Year 2023

Societal CDMO, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Societal CDMO, Inc. Reduces its Workforce by 26 Positions Across All Aspects of the Business

High number of new directors

Price target decreased by 18% to US$2.30

Societal CDMO, Inc. has completed a Follow-on Equity Offering.

Societal Cdmo Announces Appointment of Matt Arens to Board of Directors

Consensus EPS estimates fall by 18%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS misses analyst expectations

Societal CDMO, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Share price stability

Does Societal CDMO (NASDAQ:SCTL) Have A Healthy Balance Sheet?

Societal CDMO Receives Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Societal CDMO, Inc. Reaffirms 2023 Financial Guidance

Societal CDMO, Inc. to Report Q1, 2023 Results on May 10, 2023

Forecast to breakeven in 2025

Price target decreased by 13% to US$3.64

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 19% to US$5.00

Consensus EPS estimates fall by 16%

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year 2022

Societal CDMO, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Societal CDMO signs two CDMO service agreements

Societal CDMO, Inc. Appoints Elena Cant as Board of Directors

Societal stock soars 20% on signing 2 manufacturing contracts

Societal CDMO estimates to receive up to $50M on real estates' sales

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Societal CDMO, Lannett amend license and supply deal

Railroad Ranch Capital Engages in Discussions with Societal CDMO

Societal Cdmo Unveils 20/80 Second Source Technical Transfer Service Model, Offering Cost and Time Savings for Pharmaceutical Manufacturing

Consensus forecasts updated

Societal CDMO, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q1, 2022 Results on May 11, 2022

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Price target decreased to US$5.00

Societal CDMO, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Recro Pharma, Inc. Provides Earnings Guidance for the Year 2022

Recro Pharma, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Is Recro Pharma (NASDAQ:REPH) A Risky Investment?

Third quarter 2021 earnings released: US$0.068 loss per share (vs US$0.09 loss in 3Q 2020)

Consensus forecasts updated

Consensus forecasts updated

Recro Pharma, Inc. (NasdaqCM:REPH) acquired IRISYS, LLC from EPS Americas, Corp., IriSys, Inc. and Continent Pharmaceuticals U.S., Inc. for $51.7 million.

Second quarter 2021 earnings released: EPS US$0.032 (vs US$0.26 loss in 2Q 2020)

Recro Pharma, Inc.(NasdaqCM:REPH) dropped from Russell 3000E Growth Index

Recro Pharma, Inc. Expands Capabilities for Growing Clinical Trial Services Offerings